PRMT3 inhibitor SGC707 reduces triglyceride levels and induces pruritus in Western-type diet-fed LDL receptor knockout mice

Autor: de Jong, Laura M, Zhang, Zhengzheng, den Hartog, Yvette, Sijsenaar, Timothy J P, Martins Cardoso, Renata, Manson, Martijn L, Hankemeier, Thomas, Lindenburg, Peter W, Salvatori, Daniela C F, Van Eck, Miranda, Hoekstra, Menno, Anatomie en fysiologie, CS_Locomotion, CS_Cancer
Přispěvatelé: Anatomie en fysiologie, CS_Locomotion, CS_Cancer
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Zdroj: Scientific Reports, 12(1)
Scientific Reports, 12(1), 1. NLM (Medline)
Scientific Reports, Vol 12, Iss 1, Pp 1-12 (2022)
Scientific Reports
ISSN: 2045-2322
Popis: Protein arginine methyltransferase 3 (PRMT3) is a co-activator of liver X receptor capable of selectively modulating hepatic triglyceride synthesis. Here we investigated whether pharmacological PRMT3 inhibition can diminish the hepatic steatosis extent and lower plasma lipid levels and atherosclerosis susceptibility. Hereto, male hyperlipidemic low-density lipoprotein receptor knockout mice were fed an atherogenic Western-type diet and injected 3 times per week intraperitoneally with PRMT3 inhibitor SGC707 or solvent control. Three weeks into the study, SGC707-treated mice developed severe pruritus and scratching-associated skin lesions, leading to early study termination. SGC707-treated mice exhibited 50% lower liver triglyceride stores as well as 32% lower plasma triglyceride levels. Atherosclerotic lesions were virtually absent in all experimental mice. Plasma metabolite analysis revealed that levels of taurine-conjugated bile acids were ~ threefold increased (P
Databáze: OpenAIRE